Pharmaceuticals

HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. T...

2022-11-15 12:19 1788

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

ROCKVILLE, Md. and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2022-11-15 08:00 3069

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy

-- NDA acceptance takes Everest closer to making this first-in-disease treatment available for primary IgAN patients inChina -- China is home to the largest patient base for IgAN with estimated 5 million people with the disease and currently there is no approved treatment in the country -- Nefe...

2022-11-15 08:00 2748

RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published

Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib's potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) an...

2022-11-14 20:06 2145

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

* Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US andCanada, and preparation for market availability * Shareholder commitment to TauRx represen...

2022-11-14 15:00 1434

Nuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in China

SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus (RSV) in a...

2022-11-14 09:54 1862

Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting

ROCKVILLE,M.D. and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2022-11-14 08:00 3112

SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL27969, for the potential treatment of advanced solid tumors SK Biopharmaceuticals to present preclinical data on oncology candidate, SKL27969, at Society for Neuro-Oncology Conference PANGYO, South Ko...

2022-11-14 08:00 2015

Telix to Present at Jefferies London Healthcare Conference 2022

MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that DrChristian Behrenbruch,...

2022-11-11 20:00 5511

Winning the Fight Against Neuropathy in Diabetic Patients

P&G Health and medical experts share clinical guidance in the diagnosis and treatment of nerve damage among diabetic patients MANILA, Philippines, Nov. 11, 2022 /PRNewswire/ -- Ahead of World Diabetes Day 2022, P&G Health, brought together globally renowned multidisciplinary medical experts with...

2022-11-11 17:44 3025

LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

TAIPEI, Taiwan, Nov. 11, 2022 /PRNewswire/ --  Lotus Pharmaceutical (1795: TT), a multinational pharmaceutical company, today reported its financial results for the third quarter ended30 September 2022. New building Thi...

2022-11-11 17:00 3544

Bridgewest Group inks deal with Pfizer to acquire injectable manufacturing plant in Western Australia

MIAMI and PERTH, Australia, Nov. 11, 2022 /PRNewswire/ -- Global private investment firm,Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio. Today, Bridgewest Group has announced the signing of a definitive agree...

2022-11-11 10:07 3527

Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting

-   Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 -   Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...

2022-11-11 08:30 2382

Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting

SUZHOU, China, Nov. 11, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented...

2022-11-11 08:00 2994

YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer, to...

2022-11-10 22:30 2626

Novo Nordisk earns the Best Place to Work Certification in Pakistan for 2022

ISLAMABAD, Nov. 10, 2022 /PRNewswire/ -- Novo Nordisk been officially recognized as one of the Best Places to Work inPakistan and Best Place to Work for Women recognizing the company's achievements in promoting continuous learning at work and in fostering a high-performing workplace culture. Duri...

2022-11-10 21:56 2116

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

LONDON and HONG KONG, Nov. 10, 2022 /PRNewswire/ --  Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the third quarter endedSeptember 30, 2022. Third Quarter 2022 and Rec...

2022-11-10 21:30 2787

CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO

WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment ofJeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him mo...

2022-11-10 21:00 2242

Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...

2022-11-10 19:02 1894

Ascentage Pharma Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

SUZHOU, China and ROCKVILLE, Md., Nov. 9, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm ...

2022-11-10 11:36 1712
1 ... 9899100101102103104 ... 293